PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.52%
Revenue growth above 1.5x 3141.T's 2.48%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
4.09%
Gross profit growth at 50-75% of 3141.T's 6.24%. Martin Whitman would question if cost structure or brand is lagging.
-0.99%
Negative EBIT growth while 3141.T is at 9.12%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.75%
Negative operating income growth while 3141.T is at 90.38%. Joel Greenblatt would press for urgent turnaround measures.
23.00%
Net income growth under 50% of 3141.T's 46.28%. Michael Burry would suspect the firm is falling well behind a key competitor.
22.99%
EPS growth under 50% of 3141.T's 46.15%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
22.99%
Diluted EPS growth under 50% of 3141.T's 46.10%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.00%
Share reduction more than 1.5x 3141.T's 0.09%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.00%
Diluted share reduction more than 1.5x 3141.T's 0.13%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
150.12%
Similar 10Y revenue/share CAGR to 3141.T's 156.22%. Walter Schloss might see both firms benefiting from the same long-term demand.
55.30%
5Y revenue/share CAGR similar to 3141.T's 54.83%. Walter Schloss might see both companies benefiting from the same mid-term trends.
35.06%
3Y revenue/share CAGR 1.25-1.5x 3141.T's 29.21%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.20%
Net income/share CAGR above 1.5x 3141.T's 105.53% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
18.63%
Below 50% of 3141.T's 42.11%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
27.20%
Positive short-term CAGR while 3141.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
325.14%
10Y equity/share CAGR above 1.5x 3141.T's 165.36%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
83.13%
5Y equity/share CAGR 1.25-1.5x 3141.T's 67.51%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
35.58%
3Y equity/share CAGR similar to 3141.T's 33.24%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
100.00%
Below 50% of 3141.T's 318.46%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
118.18%
5Y dividend/share CAGR above 1.5x 3141.T's 61.90%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
118.18%
3Y dividend/share CAGR above 1.5x 3141.T's 25.93%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
12.35%
AR growth well above 3141.T's 0.53%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.44%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
10.86%
Asset growth above 1.5x 3141.T's 0.22%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.19%
1.25-1.5x 3141.T's 2.69%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
218.26%
We have some new debt while 3141.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
5.27%
SG&A growth well above 3141.T's 0.87%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.